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(patient severity), biochemical parameters (lipids, glucose, etc.)
and cost model. The general morbidity charge was quantiﬁed
beginning from Adjusted Clinical Groups (http://www.acg.
jhph.edu). The program provides the utilization bands of
resources (RUB, co-morbidities levels). It was considered ﬁxed/
semi-ﬁxed cost structure/salary/services) and variable one
(diagnostics/therapeutical requests, referrals, drugs). Logistical
regression analysis was effected (procedure: enter) and the cova-
riance (ANCOVA) for the correction of the models (procedure:
Bonferroni), according to the recommendations of Thompson-
Barber. Program SPSSWIN; p < 0.05. RESULTS: A total of
35,207 subjects 44 years were studied, 10.9% (95% CI: 13.3–
15.1%) show osteoporosis (average aged: 62.5  11.8 years;
woman: 94.4%). The patients with osteoporosis presented main
general morbidity (RUB: 2.9  0.6 vs. 2.7  0.7; episodes:
8.0  4.5 vs. 5.7  3.7), total cholesterol (213.2  36.1 vs.
208.9  30.9 mg/ml), visits (12.9  10.9 vs. 9.6  9.3) and
polypharmacy (41.2% vs. 22.2%), p < 0.001. The osteoporosis
had an independent association in presence from fracture
(OR = 1.4), ﬁbromyalgia (OR = 1.3), dyslipidemia (OR = 1.3),
asthma (OR = 1.2), depression (OR = 1.2) y thyroid diseases
(OR = 1.2), p < 0.001. The average unitary/total cost adjusted
for year, gender and RUB was €1387.28 vs. €808.98; and the
pharmaceutical of €1018.62 vs. €522.33; p < 0.001. All compo-
nents of outpatient management costs were signiﬁcantly higher in
the osteoporosis group. Eighteen percent of the total cost was
related to drugs. CONCLUSIONS: Patients with osteoporosis
presented a high morbidity (general) and speciﬁc one, existing
differences of gender (women), producing a high consume of
sanitary recourses.
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OBJECTIVES: 1) To assess the willingness of patients to
provide information about medical treatment, and 2) to prac-
tically demonstrate that useful information can be collected
METHODS: Public acceptability towards reporting side-effects
and efﬁcacy of medical treatments was assessed by 1) online
questionnaire, and 2) assisted questionnaire. Results from the
ﬁrst 137 respondents to the on-line questionnaire and 115
respondents to the assisted questionnaire are reported. A total
of 110 leaﬂets were distributed inviting patients to log on to a
dedicated website and provide information on post-vaccination
symptoms. Information was gathered on the day of vaccina-
tion, two days later and at day eight. RESULTS: A total of
94% of interviewees were aware of the possibility of side
effects. Of interviewees who had personal experience of side
effects, 39% did not report them. The perceived principle
conduit (81%) for reporting was to the physician. The moti-
vating factors for reporting adverse drug reactions (ADR’s) in
order of frequency was stated to be, ensuring medical safety of
others (31%), ensuring their own future good health (28%) the
advice of pharmacists/nurses (12%) and ﬁnancial incentives if
available (7%). A total of 73% reported willingness to report
side-effects via the Internet. A total of 110 leaﬂets were distrib-
uted at an inﬂuenza vaccine clinic inviting patients to log on to
an interactive website and provide information. 73 (66%) reg-
istered on the day of vaccination, 70 (96%) responded at day
two and 66 (90%) at day eight. Statistics on pain and discom-
fort demonstrate that while the majority of patients have no
pain, 8% experienced signiﬁcant discomfort and 3% pain for
greater than one hour. Of side effects reported, none required
medical attention and the majority were self-limiting. CON-
CLUSIONS: We have conﬁrmed that patients are willing to
provide information about medical treatment via an interactive
web-based system. This technique has potential for the conduct
of naturalistic studies and for post-marketing surveillance.
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OBJECTIVES: When conducting systematic reviews of ran-
domised controlled trials (RCTs), an important step is to criti-
cally assess the quality of included studies. As emphasis on sound
trial design has increased over the years, we sought to establish
how quality of studies included in systematic reviews is associ-
ated with the publication year of those studies. METHODS: We
analysed the studies included in 4 large, clinical systematic
reviews of randomised controlled trials conducted by Heron in
the last 6 months. These covered 4 disease areas: oncology,
hyperlipidaemia, anaesthesia, and serious bacterial infection. The
data extracted included a critical appraisal of study quality based
on means of quality scales. These were the Jadad scale, which
assesses randomisation, blinding, patient attrition and reporting
quality and gives a score from 1 (low) to 5 (high), and the
allocation concealment grade, which assess whether allocation to
treatment was adequately concealed. We analysed trends in both
Jadad score and allocation concealment grade by year of publi-
cation, with stratiﬁcation by disease area. RESULTS: A total of
291 trials were included in the analyses from the 4 reviews. Most
of these were carried out between 1981–2008. The average
overall Jadad score was 2.3, suggesting low overall trial quality.
Jadad score increased from a mean of 1.4 over the period 1981–
1986 to 2.9 over the period 2001–2006. Furthermore there was
an increase in the percentage of high quality (Jadad score 4–5)
trials—from 6% in 1981–1986 to 36% in 2001–2006. Only 3%
of RCTs from the period 1981–1990 recorded adequate alloca-
tion concealment; this increased to 26% over the period 1996–
2006. CONCLUSIONS: There was an observable increase in
trial quality over the period analysed. However, the mean Jadad
score, and the proportion of trials with adequate concealment of
allocation remained low, even by 2006, indicating the need for
continued attention to study quality.
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OBJECTIVES: Although effective post-approval communication
is vital in building awareness in the clinical community of newly
approved and recommended drugs, the development of such
communications can often have a lower priority than supporting
a drug through its formal regulatory submission. In this study we
considered how standard Excel-based cost effectiveness models
could be adapted to enhance communication of economic value.
METHODS: Even with a clear and positive regulatory approval
and recommendation, from groups such as National Institute for
Health and Clinical Excellence (NICE), an additional hurdle is
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